Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;105(1):44-51.
doi: 10.1007/s12185-016-2081-4. Epub 2016 Aug 24.

Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia

Affiliations

Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia

Julie Waisbren et al. Int J Hematol. 2017 Jan.

Abstract

Patients with myelodysplastic syndrome (MDS) who present with isolated thrombocytopenia (TCP) constitute a poorly described subgroup. The aim of the present study was to retrospectively evaluate disease characteristics and prognosis in patients with MDS and isolated TCP at a tertiary care center. Fifty patients (12 %) had isolated thrombocytopenia as the first presentation of MDS. Patients had varying MDS sub-classifications and cytogenetic profiles. The most common IPSS-R risk score was low (n = 24), although half of the patients had either IPSS-R intermediate (n = 18), high or very high risk disease (n = 7). Leukemic transformation occurred in 10 patients and there were 14 deaths (28 %) amongst all IPSS-R risk scores. Therapeutic agents used in this patient subgroup included hypomethylating agents and thrombopoietin receptor agonists. Overall, MDS with isolated TCP did not appear to have an inherently indolent course, as has been suggested previously. Future studies are needed to improve risk stratification, identify relevant contributors to disease pathogenesis, and better define treatment modalities.

Keywords: Acute Myeloid Leukemia; Myelodysplastic syndrome; Myeloid leukemia and dysplasia; Thrombocytopenia; Thrombopoietin analogs.

PubMed Disclaimer

References

    1. Korean J Lab Med. 2010 Apr;30(2):105-10 - PubMed
    1. Blood. 2006 Jul 15;108(2):419-25 - PubMed
    1. N Engl J Med. 2011 Jun 30;364(26):2496-506 - PubMed
    1. J Clin Oncol. 2013 Jul 20;31(21):2671-7 - PubMed
    1. J Hematol Oncol. 2014 Apr 22;7:36 - PubMed

MeSH terms

LinkOut - more resources